Acino announces collaboration with Janssen to strengthen patient access in South Africa
Acino South Africa to market and sell several Janssen products mainly within the pain, neuroscience and anti-fungal therapeutic areas to enhance patient access.
JOHANNESBURG, South Africa, 15 May 2023 – Acino Pharma (“Acino”) and the Janssen Pharmaceutical Companies of Johnson & Johnson in South Africa (“Janssen”) have signed an exclusive agreement to market and sell several Janssen products mainly within the pain, neuroscience and anti-fungal therapeutic areas to enhance patient access in South Africa.
This collaboration supports Acino’s long-term strategy and purpose to increase patients’ access to high-quality medicines in the areas where they need them most. Acino remains committed to delivering greater value to its patients, healthcare providers and industry partners in South Africa by expanding its offering across major therapeutic areas and leveraging its commercial capabilities in the region.
This agreement comes on the heels of the recent acquisition of selected trusted prescription drugs from Aspen Pharmacare, another testimony of Acino’s ambition to provide effective healthcare solutions that improve people’s lives.
John Norman, Regional Managing Director, Africa said: “I am delighted to sign this collaboration agreement with Janssen. Acino is fully aligned to Janssen’s priority of ensuring patient wellbeing by providing access to these important brands that further strengthen our pain, CNS, and anti-fungal portfolios. We are committed and look forward to continued collaboration with Janssen in other areas of our businesses.”
The agreement was signed by Ahmed El Hofy, Managing Director, Janssen South Africa and John Norman, Regional Managing Director, Africa at Acino, in a signing ceremony held on 11 May 2023, and attended by Deputy Head of Mission from the Belgian Embassy, Bart De Wolf, as well as other special guests.
Acino is a Swiss pharmaceutical company headquartered in Zurich with a clear focus on selected markets in the Middle East, Africa, Russia, the CIS Region, and Latin America. Acino is part of ADQ, an Abu Dhabi-based investment and holding company. We deliver quality pharmaceuticals to promote affordable healthcare in these emerging markets and leverage our high-quality pharmaceutical manufacturing capabilities and network to supply leading companies through contract manufacturing and out-licensing. Acino has attained Level 1 BBBEE status in South Africa in 2020 – 2023.
For more information, please contact:
Larisa Bernstein, Global Head of Communications, Acino